Tags

Type your tag names separated by a space and hit enter

Immunogenicity and safety of standard-titer AIK-C measles vaccine in nine-month-old infants.
Viral Immunol. 1999; 12(4):343-8.VI

Abstract

Because of the interference by maternal antibody before 1 year of age, the Schwarz strain of measles vaccine, which has been routinely used in Taiwan, must be given at 9 months and 15 months of age to ensure an optimal immune response. The AIK-C strain of measles vaccine has been reported to be highly immunogenic. This study evaluated the immunogenicity and safety of the AIK-C vaccine in 9-month-old Taiwanese infants. A total of 135 infants were recruited and were randomly assigned to receive either Schwarz vaccine (68 cases) or AIK-C vaccine (67 cases). Measles antibodies were assayed before and 1 month after the vaccination. Sixty-five (97%) infants who received the AIK-C vaccine seroconverted after the vaccination, whereas the seroconversion rate in those receiving the Schwarz vaccine was 77% (P = 0.001). The incidences of adverse reactions were comparable between the two groups. We conclude that even in 1990s, the failure rate of Schwarz vaccine in 9-month-old infants is still high. The AIK-C vaccine is more immunogenic in infants and its long-term immunogenicity and safety deserve further evaluation.

Authors+Show Affiliations

Department of Pediatrics, Taipei Municipal Ho-Ping Hospital, Taiwan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

10630793

Citation

Tsai, H Y., et al. "Immunogenicity and Safety of Standard-titer AIK-C Measles Vaccine in Nine-month-old Infants." Viral Immunology, vol. 12, no. 4, 1999, pp. 343-8.
Tsai HY, Huang LM, Shih YT, et al. Immunogenicity and safety of standard-titer AIK-C measles vaccine in nine-month-old infants. Viral Immunol. 1999;12(4):343-8.
Tsai, H. Y., Huang, L. M., Shih, Y. T., Chen, J. M., Jiang, T. M., Tsai, C. H., & Lee, C. Y. (1999). Immunogenicity and safety of standard-titer AIK-C measles vaccine in nine-month-old infants. Viral Immunology, 12(4), 343-8.
Tsai HY, et al. Immunogenicity and Safety of Standard-titer AIK-C Measles Vaccine in Nine-month-old Infants. Viral Immunol. 1999;12(4):343-8. PubMed PMID: 10630793.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunogenicity and safety of standard-titer AIK-C measles vaccine in nine-month-old infants. AU - Tsai,H Y, AU - Huang,L M, AU - Shih,Y T, AU - Chen,J M, AU - Jiang,T M, AU - Tsai,C H, AU - Lee,C Y, PY - 2000/1/12/pubmed PY - 2000/2/26/medline PY - 2000/1/12/entrez SP - 343 EP - 8 JF - Viral immunology JO - Viral Immunol VL - 12 IS - 4 N2 - Because of the interference by maternal antibody before 1 year of age, the Schwarz strain of measles vaccine, which has been routinely used in Taiwan, must be given at 9 months and 15 months of age to ensure an optimal immune response. The AIK-C strain of measles vaccine has been reported to be highly immunogenic. This study evaluated the immunogenicity and safety of the AIK-C vaccine in 9-month-old Taiwanese infants. A total of 135 infants were recruited and were randomly assigned to receive either Schwarz vaccine (68 cases) or AIK-C vaccine (67 cases). Measles antibodies were assayed before and 1 month after the vaccination. Sixty-five (97%) infants who received the AIK-C vaccine seroconverted after the vaccination, whereas the seroconversion rate in those receiving the Schwarz vaccine was 77% (P = 0.001). The incidences of adverse reactions were comparable between the two groups. We conclude that even in 1990s, the failure rate of Schwarz vaccine in 9-month-old infants is still high. The AIK-C vaccine is more immunogenic in infants and its long-term immunogenicity and safety deserve further evaluation. SN - 0882-8245 UR - https://www.unboundmedicine.com/medline/citation/10630793/Immunogenicity_and_safety_of_standard_titer_AIK_C_measles_vaccine_in_nine_month_old_infants_ L2 - https://www.liebertpub.com/doi/10.1089/vim.1999.12.343?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -